A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis

Neuroepidemiology

Volumn 40, Issue 3, 2013, Pages 147-153

  Pozuelo Moyano, Beatriz ^a,c   Benito León, Julián ^a,b,c   Mitchell, Alex J ^d   Hernández Gallego, Jesús ^a,c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Multiple sclerosis; Systematic review; Treatment; Vitamin D

Indexed keywords

CALCITRIOL; COLECALCIFEROL; ERGOCALCIFEROL; GLATIRAMER; INTERFERON; PLACEBO;

BRAIN DAMAGE; DRUG DOSE INCREASE; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; META ANALYSIS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SCORING SYSTEM; SYSTEMATIC REVIEW;

ANIMALS; DOUBLE-BLIND METHOD; HUMANS; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VITAMIN D;

EID: 84871190730     PISSN: 02515350     EISSN: 14230208     Source Type: Journal    
DOI: 10.1159/000345122     Document Type: Review

References (37)

1. Pugliatti M, Sotgiu S, Rosati G: The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002; 104: 182-191.
2. Benito-Leon J, Martin E, Vela L, Villar ME, Felgueroso B, Marrero C, Guerrero A, Ruiz-Galiana J: Multiple sclerosis in Mostoles, central Spain. Acta Neurol Scand 1998; 98: 238-242.
3. Benito-Leon J: Multiple sclerosis: is prevalence rising and if so why? Neuroepidemiology 2011; 37: 236-237.
4. Poser CM, Brinar VV: The accuracy of prevalence rates of multiple sclerosis: a critical review. Neuroepidemiology 2007; 29: 150-155.
5. Benito-Leon J, Morales JM, Rivera-Navarro J, Mitchell A: A review about the impact of multiple sclerosis on health-related quality of life. Disabil Rehabil 2003; 25: 1291-1303.
6. Mitchell AJ, Benito-Leon J, Gonzalez JM, Rivera-Navarro J: Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol 2005; 4: 556-566.
7. Rivera-Navarro J, Benito-Leon J, Oreja-Guevara C, Pardo J, Dib WB, Orts E, Bello M; Caregiver Quality of Life in Multiple Sclerosis (CAREQOL-MS) Study Group: Burden and health-related quality of life of Spanish caregivers of persons with multiple sclerosis. Mult Scler 2009; 15: 1347-1355.
8. Benito-Leon J, Rivera-Navarro J, Guerrero AL, de Las Heras V, Balseiro J, Rodriguez E, Bello M, Martinez-Martin P; Caregiver Quality of Life in Multiple Sclerosis (CAREQOLMS) Study Group: The CAREQOL-MS was a useful instrument to measure caregiver quality of life in multiple sclerosis. J Clin Epidemiol 2011; 64: 675-686.
9. Benito-Leon J, Mitchell AJ, Rivera-Navarro J, Morales-Gonzalez JM: Impaired healthrelated quality of life predicts progression of disability in multiple sclerosis. Eur J Neurol 2012, DOI: 10.1111/j.1468-1331.2012.03792.x.
10. Benito-Leon J, Martinez-Martin P: Healthrelated quality of life in multiple sclerosis (in Spanish). Neurologia 2003; 18: 210-217.
11. Rivera-Navarro J, Benito-Leon J: The social dimension of the quality of life in multiple sclerosis (in Spanish). Rev Neurol 2011; 52: 127, author reply 127-128.
12. Rivera-Navarro J, Benito-Leon J, Morales-Gonzalez JM: Searching for more specific dimensions for the measurement of quality of life in multiple sclerosis (in Spanish). Rev Neurol 2001; 32: 705-713.
13. Rivera-Navarro J, Morales-Gonzalez JM, Benito-Leon J; Madrid Demyelinating Diseases Group (GEDMA): Informal caregiving in multiple sclerosis patients: data from the Madrid Demyelinating Disease Group study. Disabil Rehabil 2003; 25: 1057-1064.
14. Benito-Leon J, Morales JM, Rivera-Navarro J: Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients. Eur J Neurol 2002; 9: 497-502.
15. Ascherio A, Munger KL: Epstein-Barr virus infection and multiple sclerosis: a review. J Neuroimmune Pharmacol 2010; 5: 271-277.
16. Benito-Leon J, Pisa D, Alonso R, Calleja P, Diaz-Sanchez M, Carrasco L: Association between multiple sclerosis and candida species: evidence from a case-control study. Eur J Clin Microbiol Infect Dis 2010; 29: 1139-1145.
17. Ho SL, Alappat L, Awad AB: Vitamin D and multiple sclerosis. Crit Rev Food Sci Nutr 2012; 52: 980-987.
18. Holick MF: Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
19. Stroud ML, Stilgoe S, Stott VE, Alhabian O, Salman K: Vitamin D -a review. Aust Fam Physician 2008; 37: 1002-1005.
20. Saltyte Benth J, Myhr KM, Loken-Amsrud KI, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Holmoy T: Modelling and prediction of 25-hydroxyvitamin D levels in Norwegian relapsing-remitting multiple sclerosis patients. Neuroepidemiology 2012; 39: 84-93.
21. Ascherio A, Munger KL, Simon KC: Vitamin D and multiple sclerosis. Lancet Neurol 2010; 9: 599-612.
22. McDowell TY, Amr S, Culpepper WJ, Langenberg P, Royal W, Bever C, Bradham DD: Sun exposure, vitamin D and age at disease onset in relapsing multiple sclerosis. Neuroepidemiology 2011; 36: 39-45.
23. Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, Dwyer T, Gies P, van der Mei I: Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010; 68: 193-203.
24. Jagannath VA, Fedorowicz Z, Asokan GV, Robak EW, Whamond L: Vitamin D for the management of multiple sclerosis. Cochrane Database Syst Rev 2010; (12): CD008422.
25. Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, Gagne D, D'Souza C, Ursell M, O'Connor P: A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010; 74: 1852-1859.
26. Wingerchuk DM, Noseworthy JH: Randomized controlled trials to assess therapies for multiple sclerosis. Neurology 2002; 58: S40-S48.
27. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
28. Mosayebi G, Ghazavi A, Ghasami K, Jand Y, Kokhaei P: Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Invest 2011; 40: 627-639.
29. Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, Egan GF, Mitchell PJ, Harrison LC, Butzkueven H, Kilpatrick TJ: A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011; 77: 1611-1618.
30. Kampman MT, Steffensen LH, Mellgren SI, Jorgensen L: Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler 2012; 18: 1144-1151.
31. Soilu-Hänninen M, Aivo J, Lindstrom BM, Elovaara I, Sumelahti ML, Farkkila M, Tienari P, Atula S, Sarasoja T, Herrala L, Keskinarkaus I, Kruger J, Kallio T, Rocca MA, Filippi M: A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83: 565-571.
32. Shaygannejad V, Janghorbani M, Ashtari F, Dehghan H: Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Mult Scler Int 2012; 2012: 452541.
33. Aivo J, Lindsrom BM, Soilu-Hanninen M: A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Mult Scler Int 2012; 2012: 802796.
34. Steffensen LH, Jorgensen L, Straume B, Mellgren SI, Kampman MT: Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. J Neurol 2011; 258: 1624-1631.
35. Simon KC, Munger KL, Kraft P, Hunter DJ, De Jager PL, Ascherio A: Genetic predictors of 25-hydroxyvitamin D levels and risk of multiple sclerosis. J Neurol 2011; 258: 1676-1682.
36. Smolders J, Hupperts R, Barkhof F, Grimaldi LM, Holmoy T, Killestein J, Rieckmann P, Schluep M, Vieth R, Hostalek U, Ghazi-Visser L, Beelke M; SOLAR study group: Efficacy of vitamin D(3) as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a phase II, multicenter, doubleblind, randomized, placebo-controlled trial. J Neurol Sci 2011; 311: 44-49.
37. Dorr J, Ohlraun S, Skarabis H, Paul F: Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials 2012; 13: 15.